|
Neuronal nitric oxide synthase (nNOS) inhibitors for targeted therapy of melanoma and neurodegenerative disorders
NU 2025-113 (NU 2018-176, NU 2024-250, NU 2025-038)
INVENTORS
Richard Silverman (Weinberg College of Arts and Sciences, Department of Chemistry)
SHORT DESCRIPTION
Novel highly selective neuronal nitric oxide synthase (nNOS) inhibitors for targeted therapy of melanoma and other cancers with high expression of nNOS (e.g., gliomas, ovarian cancer)...
Published: 2/6/2026
|
Inventor(s):
Keywords(s): AUTM26C1, BIAUTM1, Cancer/Oncology, Immunotherapy, Melanoma, Small molecule, Targeted therapy, Therapeutics
Category(s): Life Sciences > Therapeutics
|
|
Covalent PRC2 Inhibitors for Advanced Cancer Therapeutics
SHORT DESCRIPTION
Covalent inhibitors and proteolysis-targeting chimera (PROTAC) degraders targeting components of the PRC2 complex (EZH and EED) to block both enzymatic and non-enzymatic functions, offering robust anti-tumor efficacy.
INVENTORS
Gary Schiltz (Weinberg College of Arts and Sciences, Department of Chemistry)*
Jindan...
Published: 2/6/2026
|
Inventor(s):
Keywords(s): AUTM26C1, BIAUTM1, Bladder cancer, Breast cancer, Cancer/Oncology, Covalent inhibitor, Lymphoma, Melanoma, PreSeed/Seed, Prostate cancer, PROTAC, Small molecule, Targeted protein degradation, Targeted therapy, Therapeutics
Category(s): Life Sciences > Therapeutics
|